Pharmacokinetic/pharmacodynamic (PK/PD) modeling plays an important role in preclinical and clinical applications and has received widespread attention. PK/PD modeling can explore the effect of the organism on the drug and the effect of the drug on the organism, and provide a scientific and theoretical basis for a more comprehensive and accurate understanding of the effect of the drug as a function of dose (or concentration) and time, thus providing a scientific basis for the safety and efficacy of clinical drug use.
PK/PD modeling refers to PK- and PD-driven exploratory analyses based on mathematical models. These models help to better understand the relationship between exposure (PK) and response (PD) and the variation between these relationships as a function of drug intake. PK/PD modeling uses mathematical and statistical models to describe disease progression, and it can be used as a tool to address many key questions at all stages of the drug discovery and development process with greater certainty and at lower cost. In silico modelling combines the advantages of in vivo and in vitro experiments without the ethical considerations and lack of control of in vivo experiments. Unlike in vitro experiments, which exist in isolation, in silico models allow for a virtually unlimited number of parameters, which makes the results more applicable to the entire organism. With the improvement of simulation software and standardization of simulation conditions, PK/PD models will certainly play a fuller role in the future of drug development and accelerate the drug development process.
|Understand the time course of drug concentration and quantify dose-concentration relationships after administration of various formulations.
|Describe the most common methods of drug absorption after extravascular administration.
|Describe the absorption after extravascular administration, where the drug is absorbed at a constant rate.
|Estimates the rate and extent of absorption of various formulations via extravascular routes.
|A formulation method that prolongs the time of drug release from the delivery system to reduce the frequency of administration.
|Direct Effect Models
|The efficacy is linearly related to the drug concentration or logarithm of the drug concentration.
|Indirect Response Models
|Drugs could stimulate or inhibit the generation or dissipation of drug responses, causing a delay.
|Biophase Distribution Model
|The delay between drug concentration and therapeutic effect is attributed to the time it takes for the drug in the plasma to be distributed to the target site.
PK/PD modeling integrates variables such as time and effect as well as variables (e.g., gender, age, etc.), sets the dose and the degree of variability, and fits the data. Through various parameters, the time-dependent process and the variability characteristics of the effect of a drug are revealed. PK/PD modeling helps in drug screening and accelerates the process of new drug development. PK/PD modeling has been widely used not only in the clinical trial stage but also in other stages of new drug development such as screening of active compounds, formulation design, new formulation evaluation, preclinical pharmacology, and market evaluation.
PK/PD modeling is an integral component of drug discovery and development and is a mathematical approach to the study of PK. BOC Sciences offers superior PK/PD modeling services to support all stages of drug development projects. PK/PD modeling can provide effective theoretical guidance for new drug evaluation and dramatically reduce cycle time and save resources. Contact us to learn how our PK/PD modeling can benefit your project.